2018
The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study
Yaesoubi R, Trotter C, Colijn C, Yaesoubi M, Colombini A, Resch S, Kristiansen PA, LaForce FM, Cohen T. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study. PLOS Medicine 2018, 15: e1002495. PMID: 29364884, PMCID: PMC5783340, DOI: 10.1371/journal.pmed.1002495.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsMeningococcal casesConjugate vaccineMeningitis beltVaccination strategiesMeningococcal serogroupsStrain replacementNationwide immunization campaignPolyvalent meningococcal vaccineMeningococcal conjugate vaccineCurrent World Health OrganizationAfrican meningitis beltAlternative vaccination strategiesAlternative vaccination policiesWorld Health OrganizationMeningococcal transmissionReactive campaignsMeningococcal vaccineImmunization campaignVaccination policyPolyvalent vaccineMeningitis epidemicsReactive vaccinationVaccine policyVaccine price
2014
On the spread and control of MDR-TB epidemics: An examination of trends in anti-tuberculosis drug resistance surveillance data
Cohen T, Jenkins HE, Lu C, McLaughlin M, Floyd K, Zignol M. On the spread and control of MDR-TB epidemics: An examination of trends in anti-tuberculosis drug resistance surveillance data. Drug Resistance Updates 2014, 17: 105-123. PMID: 25458783, PMCID: PMC4358299, DOI: 10.1016/j.drup.2014.10.001.Peer-Reviewed Original ResearchConceptsMDR-TBTB casesResistant tuberculosisAbsolute burdenSurveillance dataMDR-TB epidemicDrug-resistant TBMultidrug-resistant tuberculosisDrug-resistant tuberculosisNotified TB casesResistance surveillance dataSufficient surveillance dataWorld Health OrganizationBurden settingsTuberculosis controlUnadjusted analysesSignificant linear trendSurveillance indicatorsRobust surveillance systemHealth OrganizationTuberculosisBurdenSurveillance systemSettingLinear trendBacillus Calmette-Guérin and Isoniazid Preventive Therapy Protect Contacts of Patients with Tuberculosis
Zelner JL, Murray MB, Becerra MC, Galea J, Lecca L, Calderon R, Yataco R, Contreras C, Zhang Z, Grenfell BT, Cohen T. Bacillus Calmette-Guérin and Isoniazid Preventive Therapy Protect Contacts of Patients with Tuberculosis. American Journal Of Respiratory And Critical Care Medicine 2014, 189: 853-859. PMID: 24592878, PMCID: PMC4225829, DOI: 10.1164/rccm.201310-1896oc.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overAntitubercular AgentsBCG VaccineChildChild, PreschoolContact TracingFemaleFollow-Up StudiesHumansInfantIsoniazidMaleMiddle AgedModels, StatisticalModels, TheoreticalMultivariate AnalysisOdds RatioPeruProspective StudiesTreatment OutcomeTuberculosis, PulmonaryYoung AdultConceptsIsoniazid preventive therapyAge-specific efficacyLatent TB infectionIncident tuberculosisHousehold contactsTB diseaseTB infectionPulmonary tuberculosisRisk ratioUse of IPTObservational prospective cohort studyBacillus Calmette-Guérin (BCG) vaccinationHigh TB burden settingsAdditional TB casesHIV-positive contactsIncident pulmonary tuberculosisHIV-negative childrenProspective cohort studyPublic Health CenterBacillus Calmette-GuérinYear-long followWorld Health OrganizationCohort studyPreventive therapyTB cases
2013
Community-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysis
Mills HL, Cohen T, Colijn C. Community-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysis. Science Translational Medicine 2013, 5: 180ra49. PMID: 23576815, PMCID: PMC3714172, DOI: 10.1126/scitranslmed.3005260.Peer-Reviewed Original ResearchConceptsDrug-resistant TBIPT interventionDrug-sensitive infectionsIsoniazid-resistant TBHIV/TBRisk of progressionHigh HIV prevalenceDrug-resistant diseaseIsoniazid-resistant Mycobacterium tuberculosisSymptom-free individualsSignificant elevated riskDrug-resistant strainsWorld Health OrganizationActive TBTB controlResistant tuberculosisHIV prevalenceTuberculosis controlIPT programElevated riskHost immunityMycobacterium tuberculosisHealth OrganizationSelective suppressionInterventionBayesian Estimation of Mixture Models with Prespecified Elements to Compare Drug Resistance in Treatment-Naïve and Experienced Tuberculosis Cases
Izu A, Cohen T, DeGruttola V. Bayesian Estimation of Mixture Models with Prespecified Elements to Compare Drug Resistance in Treatment-Naïve and Experienced Tuberculosis Cases. PLOS Computational Biology 2013, 9: e1002973. PMID: 23555210, PMCID: PMC3605089, DOI: 10.1371/journal.pcbi.1002973.Peer-Reviewed Original ResearchConceptsTreatment-experienced patientsDrug-resistant strainsMultiple drug-resistant strainsTreatment-naïve patientsDrug-resistant tuberculosisMycobacterium tuberculosis isolatesWorld Health OrganizationDrug resistance pathwaysTreatment-naïveTuberculosis casesTuberculosis isolatesWorldwide surveillanceDrug resistancePatientsHealth OrganizationResistant strainsResistant pathogensResistance pathwaysLow transmissibilityPathwayTuberculosis
2012
Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation
Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLOS Medicine 2012, 9: e1001347. PMID: 23185139, PMCID: PMC3502465, DOI: 10.1371/journal.pmed.1001347.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBCost-effectiveness ratioInitial diagnosisXpert MTB/RIF testMTB/RIF testXpert MTB/RIFIntroduction of XpertTB natural historyTB-HIV coinfectionMultidrug-resistant tuberculosisHigh HIV prevalenceMTB/RIFHealth system costsImplementation of XpertHealth impactsPopulation health impactCost-effectiveness resultsLong-term transmission dynamicsWorld Health OrganizationAntiretroviral therapyTB casesTB deathsTB morbidityHIV prevalenceRIF test
2011
Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009
Jenkins HE, Zignol M, Cohen T. Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009. PLOS ONE 2011, 6: e22927. PMID: 21829557, PMCID: PMC3146514, DOI: 10.1371/journal.pone.0022927.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyIncident TB casesTB casesHIV prevalence countriesHigh HIV prevalence countriesPrevalence countriesHigh HIV prevalence areasRetreatment TB casesHIV prevalence areasIsoniazid-resistant tuberculosisControl of tuberculosisEffect of INHObserved time trendsWorld Health OrganizationPreventive therapyResistant tuberculosisIncident casesTreatment successPrevalence areasIsoniazid resistanceMultidrug resistanceHealth OrganizationTuberculosisINHNational dataModelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure
Mills HL, Cohen T, Colijn C. Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure. Journal Of The Royal Society Interface 2011, 8: 1510-1520. PMID: 21508012, PMCID: PMC3163428, DOI: 10.1098/rsif.2011.0160.Peer-Reviewed Original ResearchConceptsTB diseaseLatent M. tuberculosis infectionEffects of IptHIV-endemic settingsActive tuberculosis diseaseIsoniazid preventive therapyIntact immune systemM. tuberculosis infectionWorld Health OrganizationPreventive therapyTB casesTuberculosis infectionTuberculosis diseaseClinical trialsEndemic settingsIPT programHigh riskLatent infectionSingle drugCommunity-wide levelRespiratory contactHIVImmune systemPopulation-level impactUse of IPT